Effect of single doses of pindolol and d-fenfluramine on flumazenil-induced anxiety in panic disorder patients

Imagem de Miniatura
Arquivos
art_BERNIK_Effect_of_single_doses_of_pindolol_and_dfenfluramine_2019.PDF (325.84 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2019
Editora
ELSEVIER SCIENCE BV
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
RAMOS, R. T.
HETEM, L. A. B.
GRAEFF, F.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
BEHAVIOURAL BRAIN RESEARCH, v.357, Special Issue, p.82-87, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The effects of the 5-HT1A receptor blocker pindolol and the 5-HT releasing and uptake blocking agent d-fen-fluramine, both used as indirect serotonin agonists, on flumazenil-induced acute anxiety reactions were studied in panic disorder patients to test the hypothesis that serotonin (5-HT) inhibits neural systems mediating panic attacks. Thirty never treated or drug free PD patients (16 females) aged 22-49 y (mean +/- SD, 32.9 +/- 8) received single doses of d-fenfluramine (n = 10; 30 mg, p.o.), pindolol (n = 10; 5 mg, p.o.), or placebo (n = 10) 90 and 45 min before a challenge test with flumazenil (1.5 mg, i.v., in 10 min), under double-blind conditions. Panic attacks occurred in 5 control subjects (placebo-flumazenil group), 5 subjects in the pindolol group and in 7 in the d-fenluramine pre-treated patients. Patients experiencing anxiety attacks following flumazenil reported higher increases in anxiety scores. Respiratory rate increases were not different between patients experiencing or not a panic attack. Despite sample size limitation, this study suggests that flumazenil induced anxiety reaction is not a good pharmacological model of panic attacks, considering the absence of serotonergic modulation of its effects.
Palavras-chave
Flumazenil, Pindolol, D-fenfluramine, Serotonin, Panic disorder
URI
https://observatorio.fm.usp.br/handle/OPI/31005
Referências
  1. AELLIG WH, 1982, BRIT J CLIN PHARMACO, V13, pS187, DOI 10.1111/j.1365-2125.1982.tb01909.x
  2. American Psychiatric Association, 1994, DIAGN STAT MAN MENT
  3. Andree B, 1999, PSYCHOPHARMACOLOGY, V144, P303, DOI 10.1007/s002130051009
  4. BANDELOW B, 1995, INT CLIN PSYCHOPHARM, V10, P73, DOI 10.1097/00004850-199506000-00003
  5. BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
  6. BECKETT AH, 1972, J PHARM PHARMACOL, V24, P108, DOI 10.1111/j.2042-7158.1972.tb08942.x
  7. Bell C, 2002, J PSYCHOPHARMACOL, V16, P5, DOI 10.1177/026988110201600116
  8. BERNIK M A, 1991, Journal of Psychopharmacology, V5, P215, DOI 10.1177/026988119100500306
  9. Bernik MA, 1998, J PSYCHOPHARMACOL, V12, P146, DOI 10.1177/026988119801200205
  10. BONANNO G, 1994, J NEUROCHEM, V63, P1163
  11. BROGDEN RN, 1991, DRUGS, V42, P1061, DOI 10.2165/00003495-199142060-00010
  12. Castro ME, 2000, J NEUROCHEM, V75, P755, DOI 10.1046/j.1471-4159.2000.0750755.x
  13. Corchs F, 2015, J PSYCHOPHARMACOL, V29, P1061, DOI 10.1177/0269881115590603
  14. DEAKIN J F W, 1991, Journal of Psychopharmacology, V5, P305, DOI 10.1177/026988119100500414
  15. Del-Ben CM, 2009, NEURAL PLAST, DOI 10.1155/2009/108135
  16. Dreshfield LJ, 1996, NEUROCHEM RES, V21, P557, DOI 10.1007/BF02527753
  17. Graeff F. G., 2002, TXB BIOL PSYCHIAT, P879
  18. Graeff FG, 1996, PHARMACOL BIOCHEM BE, V54, P129, DOI 10.1016/0091-3057(95)02135-3
  19. Graeff FG, 1998, NEUROSCI BIOBEHAV R, V23, P237, DOI 10.1016/S0149-7634(98)00024-4
  20. GRIEBEL G, 1995, PSYCHOPHARMACOLOGY, V120, P57, DOI 10.1007/BF02246145
  21. Gross CT, 2012, NAT REV NEUROSCI, V13, P651, DOI 10.1038/nrn3301
  22. Hetem LAB, 1996, PSYCHOPHARMACOLOGY, V127, P276
  23. LITTLE HJ, 1987, BRAIN RES BULL, V19, P371
  24. Lowry CA, 2005, STRESS, V8, P233, DOI 10.1080/10253890500492787
  25. Maron E, 2006, NEUROPSYCHOPHARMACOL, V31, P1, DOI 10.1038/sj.npp.1300880
  26. Martinez D, 2001, NEUROPSYCHOPHARMACOL, V24, P209, DOI 10.1016/S0893-133X(00)00187-1
  27. McAskill R, 1998, BRIT J PSYCHIAT, V173, P203, DOI 10.1192/bjp.173.3.203
  28. McNaughton N, 2004, NEUROSCI BIOBEHAV R, V28, P285, DOI 10.1016/j.neubiorev.2004.03.005
  29. MCTAVISH D, 1992, DRUGS, V43, P713, DOI 10.2165/00003495-199243050-00007
  30. Millan MJ, 2003, PROG NEUROBIOL, V70, P83, DOI 10.1016/s0301-0082(03)00087-X
  31. NUTT D, 1992, BRIT J PSYCHIAT, V160, P165, DOI 10.1192/bjp.160.2.165
  32. NUTT DJ, 1990, ARCH GEN PSYCHIAT, V47, P917
  33. PERSSON A, 1989, Human Psychopharmacology, V4, P21, DOI 10.1002/hup.470040105
  34. Pobbe RLH, 2005, PSYCHOPHARMACOLOGY, V183, P314, DOI 10.1007/s00213-005-0196-z
  35. Pobbe RLH, 2011, EUR NEUROPSYCHOPHARM, V21, P306, DOI 10.1016/j.euroneuro.2010.05.004
  36. pocock S. J., 1996, CLIN TRIALS
  37. Preter M, 2008, PROG NEURO-PSYCHOPH, V32, P603, DOI 10.1016/j.pnpbp.2007.07.029
  38. Preter M, 2014, NEUROSCI BIOBEHAV R, V46, P345, DOI 10.1016/j.neubiorev.2014.03.025
  39. Raurich A, 1999, SYNAPSE, V34, P68, DOI 10.1002/(SICI)1098-2396(199910)34:1<68::AID-SYN8>3.0.CO;2-Z
  40. RICHARDS RP, 1989, XENOBIOTICA, V19, P547, DOI 10.3109/00498258909042294
  41. Sassano-Higgins SA, 2015, J PHARMACOL PHARMACO, V6, P36, DOI 10.4103/0976-500X.149144
  42. SAVIC I, 1991, LANCET, V337, P133, DOI 10.1016/0140-6736(91)90799-U
  43. Serotonin F. G. Graeff, 2004, NEUROSCI BIOBEHAV R, V28, P239
  44. Sheehan DV, 1983, ANXIETY DIS
  45. Spielberger CD, 1970, MANUAL STATE TRAIT A
  46. Spitzer R. L., 1979, SCHEDULE AFFECTIVE D
  47. Strohle A, 1998, AM J PSYCHIAT, V155, P610, DOI 10.1176/ajp.155.5.610
  48. Strohle A, 1999, BIOL PSYCHIAT, V45, P321, DOI 10.1016/S0006-3223(98)00295-9
  49. TARGUM SD, 1989, PSYCHIAT RES, V28, P295, DOI 10.1016/0165-1781(89)90210-2
  50. Viana MB, 1996, BRAZ J MED BIOL RES, V29, P639
  51. Vieira AHG, 1997, BRAZ J MED BIOL RES, V30, P887, DOI 10.1590/S0100-879X1997000700011
  52. WOODS SW, 1991, PSYCHIAT RES, V36, P115, DOI 10.1016/0165-1781(91)90124-8

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPq